- Home
- SCPQU vs BGMS Comparison
SCPQU vs BGMS Comparison
Compare SCPQU & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SCPQU | BGMS |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 5.0M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | SCPQU | BGMS |
|---|---|---|
| Price | $10.00 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.1K | ★ 147.8K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.99 | $0.74 |
| 52 Week High | $10.06 | $6.70 |
Technical Indicators
Market Signals| Indicator | SCPQU | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 40.09 |
| Support Level | N/A | $0.74 |
| Resistance Level | $10.06 | $1.12 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 20.00 | 24.28 |
Price Performance
Historical ComparisonAbout SCPQU Social Commerce Partners Corporation Unit
Social Commerce Partners Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.